Johnson & Johnson
Close on Nov 4, 2026Market cap $665.90BP/E 41.9Yield 1.86%
Johnson & Johnson SPRAVATO (esketamine) by Year
SPRAVATO (esketamine) — International operational growth YoY (%) (%)
Johnson & Johnson SPRAVATO (esketamine): 39.1% in FY2025, down 12.1 pts from a year earlier.
Where the FY2025 figure comes from
“|| Intl | 210 | 148 | 41.9 | 39.1 | 2.8”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SPRAVATO (esketamine) — International operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 39.1% | -12.1 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 51.2% | – | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) (%), annual FY2024–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-spravato-intl-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?